Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s47, 2022. DOI: 10.25251/skin.6.supp.47. Disponível em: https://skin.dermsquared.com/skin/article/view/1802. Acesso em: 19 apr. 2026.